States with medical marijuana laws saw 20 percent drop in some opioid prescriptions
States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center.
Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce opioid use.
Stories you may be interested in
New study finds cannabis effective for treating migraines
A study published last month in the Journal of Pain found a statistically significant reduction in migraine and headache symptoms and recurrences among patients who used cannabis for treatment.Smoking cannabis reduced the severity and length of migraine episodes by nearly half. Researchers concluded that headache and migraine severity were reduced by nearly 50% after using cannabis. The study, conducted by researchers…
Read More 
PTSD and Cannabis
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that occurs in people who witnessed or have gone through a traumatic event. That can include events such as natural disasters, war/combat, a serious accident, or personal assault, among others. People suffering from PTSD have disturbing thoughts and feelings related to the traumatic event that can last…
Read More 
New Feature: Calendar Integration
At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More 
More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits
Baby boomers’ marijuana use has edged upward in the past decade, but recent research suggests some still have a hard time getting a hold of the drug. Older adults want more education, more research and greater openness with their health-care providers about using medical marijuana, according to a qualitative study of older cannabis users and non-users in…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
After 50 Years, U.S. Opens The Door To More Cannabis Crops For Scientists
After more than 50 years, the federal government is lifting a roadblock to cannabis research that scientists and advocates say has hindered rigorous studies of the plant and possible drug development. Since 1968, U.S. researchers have been allowed to use cannabis from only one domestic source: a facility based at the University of Mississippi, through a…
Read More